查詢結果分析
相關文獻
- Entresto在高血壓治療的角色
- AROTINOLOL治療原發性高血壓的臨床研究
- 運動對高血壓的影響
- Unexpected Pheochromocytoma--A Case Report of Anesthesia in a Uremic Patient
- Relationship between Microalbuminuria, Left Ventricular Mass and Function in Essential Hypertension
- The Effect of Sphenopalatine Postganglionic Neurotomy on the Alteration of Local Cerebral Blood Flow of Normotensive and Hypertensive Rats in Acute Cold Stress
- 衛生教育對於榮民之家高血壓老人自我照顧行為與血壓控制之影響
- 長期阻斷內生性一氧化氮對血壓的影響:正常鼠與高血壓鼠間的比較
- Comparison of Clinical Efficacy and Adverse Effects between Extended-release Felodipine and Slow-release Diltiazem in Patients with Isolated Systolic Hypertension
- 同時多發性高血壓腦出血--病例報告
頁籤選單縮合
題 名 | Entresto在高血壓治療的角色=The Role of Entresto in Hypertension Therapy |
---|---|
作 者 | 陳柏帆; 張美枝; 林佩姿; 林育昰; 潘國利; | 書刊名 | 藥學雜誌 |
卷 期 | 34:1=134 2018.03[民107.03] |
頁 次 | 頁67-72 |
分類號 | 415.382 |
關鍵詞 | 高血壓; 健安心; 腎素-血管收縮素-醛固酮系統; Hypertension; Entresto; Rennin-angiotensin-aldosterone system; |
語 文 | 中文(Chinese) |
中文摘要 | 高血壓是許多心血管疾病的危險因子,若沒有早期發現與治療,將可能導致心肌 梗塞、中風、腎衰竭與死亡。2014年美國醫學會針對高血壓病人提供一套系統性與證 據力充分的治療指引 (The Eighth Joint National Committee;JNC8)。Valsartan-sacubitril (Entresto,健安心) 為在此之後才發展出來的新一代藥物,其結合了兩種作用機轉, 包含腎素 - 血管收縮素 - 醛固酮系統及利鈉尿胜肽系統。依據 PARADIGM-HF trial 研 究結果發現,使用 Entresto 對心衰竭的病人能有效降低再住院率與增加存活率。至於 Entresto 在治療高血壓的角色則尚未見於相關臨床治療指引,我們期待它未來有機會 變成治療高血壓的新選擇。 |
英文摘要 | Hypertension is a risk factor for many cardiovascular diseases. It may lead to myocardial infarction, stroke, kidney failure, and death, if without early detection and proper treatment.The American Medical Association provides a systematic and evidence-based treatment vasoconstrictor-aldosterone system and the natriuretic peptide system. The PARADIGM-HF trial showed that Entresto can effectively reduce rehospitalization and increase survival rate in people with heart failure. However, the role of Entresto in the treatment of hypertension is not verified. We look forward to it become a new choice for hypertension treatment. guideline (The Eighth Joint National Committee; JNC8) for hypertensive patientsin 2014. Entresto is a new generation of drug acting on two mechanisms, including the rennin-vasoconstrictor-aldosterone system and the natriuretic peptide system. The PARADIGM-HF trial showed that Entresto can effectively reduce rehospitalization and increase survival rate in people with heart failure. However, the role of Entresto in the treatment of hypertension is not verified. We look forward to it become a new choice for hypertension treatment. |
本系統中英文摘要資訊取自各篇刊載內容。